Normal Values of Brain Natriuretic Peptide in Healthy Newborn

Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud

Status: Completed

Conditions: Reference Values of BNP in Healthy Newborn

Treatments: Procedure: Blood sample and BNP measurement

Study type: Observational

Funder types: Other

Identifiers

NCT02574806

EBNPRNS01

Details and patient eligibility

About

Brain natriuretic peptide (BNP) is an important tool for diagnosis, risk stratification and prognosis in pediatric patients with heart failure1. In newborn, after delivery, the BNP plays an important role in cardiopulmonary hemodynamics by stimulating vasodilatation and diuresis. The gradual decrease in pulmonary pressure and the initiation of diuresis as expression of renal maturity could explain the subsequent decrease in serum values. This would suggest that, in healthy newborns, BNP values should be found within a given ranges. However, the evidence suggests an important variability in BNP values 2 - 4. In the other hand, in the newborn with respiratory distress BNP could have a high negative predictive value to rule out acute myocardial processes, as responsible for clinical deterioration, from infectious, metabolic or respiratory processes; with a potential of improvement in medical care. Even the increased use of this biomarker in clinical practice, until our knowledge, BNP normal values remain unknown in the healthy newborn. Therefore, the investigators performed a pioneer study to establish normal values in healthy newborn population. Multi-center, prospective and observational study was carried out. Objective: To establish normal BNP values in healthy newborn.

Enrollment: 167 patients

Sex: All

Ages: Under 1 minute old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy mother with pregnancy at term (38 to 42 gestational weeks) with adequate prenatal care.
• newborns with Apgar score ≥ 7 at 0 and 5 minutes respectively.

Exclusion criteria

• newborns of mothers with pregnancy-associated diseases.
• newborns with chromosomopathies detected during the antenatal care and newborns with signs of cardiac and/or respiratory compromise.

Trial design

167 participants in 2 patient groups

Healthy newborn

Description:

Healthy newborn at term of healthy mother.

Treatment:

Procedure: Blood sample and BNP measurement

Preeclamptic newborn

Description:

Newborn at term of mother with pre-eclampsia with severity features.

Treatment:

Procedure: Blood sample and BNP measurement